Crexendo, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Crexendo, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.17M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $60.84M | Mar 3, 2026 |
| FY2023 | Dec 31, 2023 | $14.16M | Mar 5, 2024 |
| FY2023 | Sep 30, 2023 | $13.87M | Mar 5, 2024 |
| FY2023 | Jun 30, 2023 | $12.67M | Mar 5, 2024 |
| FY2023 | Mar 31, 2023 | $12.49M | Mar 5, 2024 |
| FY2023 | Dec 31, 2022 | $11.44M | Mar 5, 2024 |
| FY2023 | Sep 30, 2022 | $9.11M | Mar 5, 2024 |
| FY2023 | Jun 30, 2022 | $8.85M | Mar 5, 2024 |
| FY2023 | Mar 31, 2022 | $8.16M | Mar 5, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.22M | Mar 3, 2026 |
| FY2025 | Sep 30, 2025 | $1.45M | Mar 3, 2026 |
| FY2025 | Jun 30, 2025 | $1.23M | Mar 3, 2026 |
| FY2025 | Mar 31, 2025 | $1.17M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $507.0K | Mar 3, 2026 |
| FY2025 | Sep 30, 2024 | $148.0K | Mar 3, 2026 |
| FY2025 | Jun 30, 2024 | $588.0K | Mar 3, 2026 |
| FY2025 | Mar 31, 2024 | $434.0K | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $61.0K | Mar 4, 2025 |
| FY2024 | Sep 30, 2023 | $1.70M | Mar 4, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.13M | Mar 3, 2026 |
| FY2025 | Sep 30, 2025 | $1.31M | Mar 3, 2026 |
| FY2025 | Jun 30, 2025 | $1.10M | Mar 3, 2026 |
| FY2025 | Mar 31, 2025 | $1.15M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $626.0K | Mar 3, 2026 |
| FY2025 | Sep 30, 2024 | $135.0K | Mar 3, 2026 |
| FY2025 | Jun 30, 2024 | $580.0K | Mar 3, 2026 |
| FY2025 | Mar 31, 2024 | $483.0K | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $38.0K | Mar 4, 2025 |
| FY2024 | Sep 30, 2023 | $364.0K | Mar 4, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.35M | Mar 3, 2026 |
| FY2025 | Sep 30, 2025 | $1.41M | Mar 3, 2026 |
| FY2025 | Jun 30, 2025 | $1.44M | Mar 3, 2026 |
| FY2025 | Mar 31, 2025 | $1.52M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $1.50M | Mar 3, 2026 |
| FY2025 | Sep 30, 2024 | $1.47M | Mar 3, 2026 |
| FY2025 | Jun 30, 2024 | $1.33M | Mar 3, 2026 |
| FY2025 | Mar 31, 2024 | $1.25M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $1.26M | Mar 4, 2025 |
| FY2024 | Sep 30, 2023 | $1.28M | Mar 4, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.30M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $6.28M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $3.50M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($411.0K) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($1.01M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $647.0K | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $1.64M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $452.0K | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $294.0K | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($1.13M) | Mar 6, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.0K | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $27.0K | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $92.0K | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $289.0K | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $101.0K | Mar 14, 2023 |
| FY2013 | Dec 31, 2013 | $0 | Mar 4, 2014 |
| FY2013 | Dec 31, 2012 | $6.0K | Mar 4, 2014 |
| FY2012 | Dec 31, 2011 | $655.0K | Mar 18, 2013 |
| FY2011 | Dec 31, 2010 | $101.0K | Mar 8, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.69M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $64.94M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $56.16M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $55.63M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $77.15M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $30.71M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $7.78M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $4.55M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $3.74M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $3.53M | Mar 6, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.87M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $13.53M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $11.55M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $14.18M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $11.22M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $4.94M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $3.40M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $2.55M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $2.11M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $3.02M | Mar 6, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.82M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $51.41M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $44.61M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $41.46M | Mar 4, 2025 |
| FY2023 | Dec 31, 2021 | $65.93M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $25.76M | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $4.39M | Mar 21, 2022 |
| FY2019 | Dec 31, 2018 | $2.00M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $1.63M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $515.0K | Mar 6, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.45M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $9.45M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $9.45M | Mar 3, 2026 |
| FY2023 | Dec 31, 2022 | $9.45M | Mar 5, 2024 |
| FY2022 | Sep 30, 2022 | $36.97M | Mar 14, 2023 |
| FY2023 | Dec 31, 2021 | $36.97M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $272.0K | Mar 14, 2023 |
| FY2020 | Dec 31, 2019 | $272.0K | Mar 9, 2021 |
| FY2020 | Dec 31, 2018 | $272.0K | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | $272.0K | Mar 3, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($81.72M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($86.79M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($88.47M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($87.95M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($52.53M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($50.09M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($58.03M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($59.17M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | ($58.94M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($58.22M) | Mar 6, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $5.48M | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | $7.47M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $17.58M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $4.18M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $1.85M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $1.28M | Mar 6, 2019 |
| FY2018 | Dec 31, 2016 | $0 | Mar 6, 2019 |
| FY2017 | Dec 31, 2015 | $1.50M | Mar 6, 2018 |
| FY2016 | Dec 31, 2014 | $2.91M | Mar 7, 2017 |
| FY2015 | Dec 31, 2013 | $3.08M | Mar 1, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.0K | Mar 3, 2026 |
| FY2024 | Dec 31, 2024 | $592.0K | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $1.05M | Mar 5, 2024 |
| FY2021 | Dec 31, 2021 | $1.87M | Mar 21, 2022 |
| FY2020 | Dec 31, 2020 | $1.94M | Mar 9, 2021 |
| FY2018 | Dec 31, 2018 | $56.0K | Mar 6, 2019 |
| FY2017 | Dec 31, 2017 | $79.0K | Mar 6, 2018 |
| FY2016 | Dec 31, 2016 | $1.12M | Mar 7, 2017 |
| FY2015 | Dec 31, 2015 | $1.14M | Mar 1, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 3, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 3, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Mar 3, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 3, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Mar 3, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Mar 3, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 4, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 4, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 3, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 3, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Mar 3, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 3, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Mar 3, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Mar 3, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 4, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 4, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 31.00M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | 27.62M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | 26.13M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | 25.67M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 22.05M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 17.98M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | 14.88M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 14.39M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | 14.29M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | 13.58M | Mar 6, 2018 |